WithdrawnPhase 2NCT04915144
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
Studying Gastroenteric neuroendocrine neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- British Columbia Cancer Agency
- Principal Investigator
- Francois Benard, MDBC Cancer
- Intervention
- 177Lu-DOTATOC(drug)
- Eligibility
- 19 years · All sexes
- Timeline
- 2023 – 2031
Study locations (1)
- BC Cancer, Vancouver, British Columbia, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04915144 on ClinicalTrials.govOther trials for Gastroenteric neuroendocrine neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07161882ALG-LungCancerRegistry (SAFRO2202)Société Algérienne de Formation et de Recherche en Oncologie
- ACTIVE NOT RECRUITINGPHASE2NCT03110978Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung CancerM.D. Anderson Cancer Center